Cathay Biotech (SH:688065)2024-04-14 07:42Financial Projections - The company expects Q1 2024 revenue to be between 650 million and 720 million CNY, representing a year-over-year increase of 28.60% to 42.45%[2] - The projected net profit attributable to shareholders for Q1 2024 is estimated to be between 94 million and 115 million CNY, reflecting a year-over-year growth of 63.65% to 100.20%[2] - The net profit attributable to shareholders after deducting non-recurring gains and losses is expected to be between 91 million and 112 million CNY, indicating a year-over-year increase of 79.04% to 120.36%[2] Previous Financial Performance - In Q1 2023, the company reported revenue of 505.45 million CNY and a net profit of 57.44 million CNY[3] Market Factors - The significant increase in sales volume and revenue is attributed to the recovery in downstream demand and the company's efforts to expand the market for new products, particularly dodecanedioic acid[5] Financial Reporting - The financial data provided is preliminary and has not been audited by an accounting firm, with final figures to be disclosed in the official Q1 2024 report[6]